AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05568277 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education on preventive health behaviors based on Pender's Health Promotion Model
Description: Pregnant women included in the study will be given education on preventive health behaviors based on Pender's Health Promotion Model on the prevention of gestational diabetes over the web (ZOOM/Teams etc.) every two weeks. Pregnant women's questions will be answered. At the end of each training, data will be collected from pregnant women and follow-up charts will be filled. The education booklet prepared by the researcher will be given to the pregnant women after the first education and will be sent to their e-mail addresses.
Study NCT06112249 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SAFE Employment Training
Description: The SAFE program includes lessons in the following areas: 1) Overview of What COVID-19 is and how it spreads 2) What is PPE and How to properly use 3) Social Distancing 4) Community Participation 5) Employment 6) Self Efficacy. We would also like to know if you learn more when the SAFE program is taught by a peer (person who also has an intellectual developmental disability).
Study NCT05520359 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobility Device
Description: Use of mobility device during session.
Study NCT05520359 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinal Stimulation
Description: A stimulator will be used non-invasively stimulate the spine at the neck and/or lower back (cervical and/or lum
Study NCT06006962 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aging Well through Interactions and Scientific Education - Action Plan
Description: 20-week program designed to provide education and individualized planning with a goal of improving brain health.
Study NCT05608707 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Description: The 12 week intervention will involve 2 weekly group exercise sessions incorporating strength and balance exercises, along with home-based exercise focused on increasing time spent walking.
Study NCT05608707 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Personalised nutrition intervention
Description: Two Plant-based Protein and Fibre (PPF) product products have been selected from six initially developed, with best amino acid blend, taste, and bioavailability. Participants will be provided with the PPFs to consume daily as part of a personalised diet over 12 weeks.
Study NCT06341504 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prevention pop-up messages
Description: Messages are shown full screen on the EGM's play screen on a fixed presentation schedule. Clock of the gambling session starts the first time the participant puts money in the EGM. From this event, messages are shown at those timepoints: \[1\] +10 minutes; \[2\] +40 minutes; \[3\] +70 minutes; \[4\] +100 minutes. Messages block the screen for 15 seconds before automatically closing. Up to 4 different messages are presented during the gambling session. Order is determined by sortition without replacement.~Messages have a warning heading Caution!. Content is, from top to bottom: (a) time spent gambling from beginning; (b) warning that gambling could lead to serious monetary loss; (c) 1 of 4 self-appraisal phrases about current gambling behaviour; (d) advice to the participant that a break could help choose what is best for them; (e) countdown before the message closes itself; (f) Health department logo is shown in the lower right corner as a more neutral endorsement of the messages.
Study NCT06341504 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mandatory time limit
Description: Activated either when (a) the previous time limit is up; or (b) the player bank meter reaches $0. When the previous time limit is up, a pop-up takes up the upper third of the play screen and requires the player to set a new time limit using one of five choice buttons (four firsts buttons: 15, 30, 45 or 60 minutes; fifth button: cash out, which prints a receipt and ends the gambling session). As the EGM cannot track who is playing, there are no limits on consecutive gambling sessions. When the player's bank meter reaches $0, the the pop-up described above appears as soon as new money is inserted in the EGM, no matter if the previous time limit is up or not.
Study NCT06341504 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mandatory time limit
Description: Activated either when (a) the previous time limit is up; or (b) the player bank meter reaches $0. When the previous time limit is up, a pop-up takes up the upper third of the play screen and requires the player to set a new time limit using one of five choice buttons (four firsts buttons: 15, 30, 45 or 60 minutes; fifth button: cash out, which prints a receipt and ends the gambling session). As the EGM cannot track who is playing, there are no limits on consecutive gambling sessions. When the player's bank meter reaches $0, the the pop-up described above appears as soon as new money is inserted in the EGM, no matter if the previous time limit is up or not.
Study NCT06341504 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Responsible gambling information
Description: Located in a submenu accessed through a button on the main touch screen. This open a window which contains basic information on randomness and responsible gambling advice. The information is presented in small white font on a black background.
Study NCT06341504 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Responsible gambling information
Description: Located in a submenu accessed through a button on the main touch screen. This open a window which contains basic information on randomness and responsible gambling advice. The information is presented in small white font on a black background.
Study NCT06341504 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electronic gambling machine (model IGT GL20)
Description: EGM model currently in use in Quebec, Canada, the location where this study is conducted. The EGMs used in this study are fully functional and unaltered except for the presentation of prevention pop-up messages in the experimental arm of this study. These machines are equipped with basics responsible gambling features, the two main ones described in this section (i.e. Mandatory time limit; Responsible gambling information). Wins/losses sequence is fully randomized and not determined beforehand.
Study NCT06653582 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Postural reeducation
Description: The program will include postural awareness, stretching, McKenzie's method, and manual therapy for 12 weeks.
Study NCT06653582 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pelvic floor exercises
Description: The program will include pelvic floor exercises for 12 weeks. Three sets of 10 long contractions will be performed, each sustained for 6-8 seconds, three times a day. After each contraction, participants will be asked to rest for the same period. Two series of 10 fast contractions will be recommended, consisting of short, quick exercises of 1- to 2-second contractions, followed by long, sustained exercises lasting 5-10 seconds.
Study NCT06341504 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electronic gambling machine (model IGT GL20)
Description: EGM model currently in use in Quebec, Canada, the location where this study is conducted. The EGMs used in this study are fully functional and unaltered except for the presentation of prevention pop-up messages in the experimental arm of this study. These machines are equipped with basics responsible gambling features, the two main ones described in this section (i.e. Mandatory time limit; Responsible gambling information). Wins/losses sequence is fully randomized and not determined beforehand.
Study NCT06341504 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Square terminal
Description: This terminal allows for buying non-alcoholic beverages (soft drinks or coffee) and chips during the experimentation. This is done to enhance the realism of the bar setting. It also allows for real cash withdrawal from bank account during gambling session. Quebec's code of conduct for EGMs commercialization prohibits retailers from having an ATM near their EGMs, and prohibits them from lending money to consumers or withdrawing cash for them to gamble. However, this rule is not always followed in practice. For this study, participants will be allowed to withdraw from their bank account, at the bar counter, if they ask for it. However, this will not be offered to them upfront.
Study NCT06341504 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Square terminal
Description: This terminal allows for buying non-alcoholic beverages (soft drinks or coffee) and chips during the experimentation. This is done to enhance the realism of the bar setting. It also allows for real cash withdrawal from bank account during gambling session. Quebec's code of conduct for EGMs commercialization prohibits retailers from having an ATM near their EGMs, and prohibits them from lending money to consumers or withdrawing cash for them to gamble. However, this rule is not always followed in practice. For this study, participants will be allowed to withdraw from their bank account, at the bar counter, if they ask for it. However, this will not be offered to them upfront.
Study NCT04834167 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OneDoc Picopulse
Description: Eligible patients will proceed to receive skin cleansing prior to OneDoc Picopulse treatment. After the cleansing, the patients will receive OneDoc Picopulse treatment for 15 mins. Patients will receive ten picopulse treatments for bi-monthly.
Study NCT05109832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14C-IMP4297
Description: 14C marked IMP4297
Study NCT06245317 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical Ventilation Mode
Description: Each arm will have a different ventilation mode according to the allocation.
Study NCT05977673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab 200mg IV day1
Study NCT06210100 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active iTBS
Description: Mag-TD stimulator
Study NCT06210100 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham iTBS
Description: Mag-TD stimulator
Study NCT04803227 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Emricasan
Description: Emricasan 25 mg BID (days 1-14). Oral (capsule) administration.
Study NCT04803227 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo BID \*days 1-14). Oral (capsule) administration.
Study NCT06237400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZG19018
Description: ZG19018 Given by PO (mouth)
Study NCT05285540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DT-216
Description: DT-216 will be administered by intravenous (IV) injection
Study NCT05285540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DT-216 matching Placebo
Description: Placebo will be administered by intravenous (IV) injection
Study NCT05044858 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Midpoint transverse process block group
Description: After marking the level of the incision by surgeon (commonly T5- T6) The patient will be situated in the lateral position, the block area will be sterilized with povidine-iodine, and high -frequency linear ultrasound probe will be placed oblique parasagittally 3 cm lateral to the spinous process at the level of skin incision. 100-mm short bevel echogenic needle (Contiplex, B.Braun, Germany) will be inserted in plane from cranial to caudal direction. The desired end point of the needle tip will be the midpoint of the line between the posterior border of transverse process and the pleura titrated bolus of 20 ml of 0.25% bupivacaine and dexamethazone 8 mg will be injected at the target site. At end of the surgery general anaesthesia will be stopped with reversal of muscle relaxation and awakening of patient
Study NCT05044858 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham group
Description: General anesthesia will be induced with the same protocol and MTP block will be done but with injection of placebo (2 ml normal saline) instead of local anesthetic .~On arrival to the PACU postoperative Numerical Rating scale at rest and coughing will be recorded, analgesia will be maintained with intravenous paracetamol 1 g every 8 h and required additional rescue analgesia (morphine) at any time will be calculated.
Study NCT04656132 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity assessment, promotion and monitoring in a preventive cardiology clinic
Description: physical activity assessment promotion and remote home step-count monitoring in a clinical cardiology center
Study NCT05448794 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: injection
Description: ultrasound-guided hydrodilatation with hypertonic Dextrose
Study NCT05507372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimozide 1 MG
Description: Dopamine Receptor Antagonist - Oral Pimozide
Study NCT05507372 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pimozide 1 MG
Description: Dopamine Receptor Antagonist - Oral Pimozide
Study NCT04780685 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: hMSC
Description: IV administration
Study NCT04780685 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hMSC
Description: IV administration
Study NCT05563987 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT-DE
Description: The acceptance and commitment therapy is a psychological component to cultivate participants' acceptance attitude to diabetes and motivate them for a value-driven persistent diabetes self-management, directed by six psychological processes in the hexagonal model of ACT, including acceptance, cognitive defusion, the present moment, self-as-context, value clarification and committed action.
Study NCT05563987 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DE
Description: DE
Study NCT06470945 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Glass ceramic sectional veneer
Description: partial laminate veneer
Study NCT06470945 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Glass ceramic laminate veneer
Description: Glass ceramic laminate veneer
Study NCT04932083 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacaine
Description: patients will be put in the sitting position and lean forward. After sterilization, Dural puncture will be performed at L4-L5 interspace or L3-L4 with a 25 gauge Quincke spinal needle.~patients will receive the local anesthetic dose of 0.5% heavy bupivacaine (12.5 mg) and 0.5 ml of sterile water will be added.
Study NCT04932083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: patients will be put in the sitting position and lean forward. After sterilization, Dural puncture will be performed at L4-L5 interspace or L3-L4 with a 25 gauge Quincke spinal needle.~patients will receive the local anesthetic dose of 0.5% heavy bupivacaine (12.5 mg) and 0.5 ml of fentanyl (25µg) will be added.
Study NCT04932083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalbuphine
Description: patients will be put in the sitting position and lean forward. After sterilization, Dural puncture will be performed at L4-L5 interspace or L3-L4 with a 25 gauge Quincke spinal needle.~patients will receive the local anesthetic dose of 0.5% heavy bupivacaine (12.5 mg) and 0.8 mg nalbuphine hydrochloride in 0.5 ml sterile water will be added.
Study NCT04932083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: patients will be put in the sitting position and lean forward. After sterilization, Dural puncture will be performed at L4-L5 interspace or L3-L4 with a 25 gauge Quincke spinal needle.~patients will receive the local anesthetic dose of 0.5% heavy bupivacaine (12.5 mg) and 0.4 ml of midazolam (2mg) + 0.1 ml of sterile water will be added.
Study NCT06267859 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: The use of a combination of microelements and vitamins against the background of physiotherapy
Description: If necessary, necessary microelements and vitamins will be added to the treatment process. At the same time, physiotherapeutic procedures will be added at the rehabilitation stage.
Study NCT05205642 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary exercise test (CPET)
Description: Cardiopulmonary exercise testing (CPET) using a Quark CPET metabolic cart (Rome, Italy) according to American Thoracic Society (ATS) guidelines. A symptom-limited test on a treadmill will be performed, using incremental ramp Bruce protocol up to exhaustion. Patients who will not be able to perform the test on a treadmill will be tested on a cycle ergometer beginning with a no-resistance warm-up lasting 2-3 minutes, followed by incrementing resistance (8-30 Watts/minute) adapted to the patient's functional capacities according to the examiner's free judgment, up to exhaustion.
Study NCT05205642 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Peripheral Arterial Tonography (PAT) using the EndoPAT™ device
Description: A volume sensor measuring reactive hyperemia is placed on the second fingertip of both hands. First the device evaluates the baseline volume of the pulse. Then, we will apply pressure that is 50 mmHg higher than the baseline systolic pressure of the examinee on the evaluated hand for five minutes, using a sphygmomanometer cuff. After the pressure is released on the evaluated hand, the new pulse volume is tested. To neutralize the effects of the autonomous systemic response, the program divides the difference of the pulse volume in the examined hand by the difference in the untested hand and we get the Reactive Hyperemic Index (RHI) which represents the endothelial function in the tested hand. During the examination, the calculated arterial tonometry graph is generated, and out of it the RHI will be automatically calculated, using the EndoPAT2000™ program.
Study NCT05205642 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Endothelin
Description: For Endothelin levels we will use the Endothelin ELISA kit from R\&D company, and for measurement 1 cc of serum will be needed.
Study NCT06374511 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Test for CMV reactivation
Description: All enrolled patients are monitored for CMV reactivation and hepatic encephalopathy using regular clinical tests or library test
Study NCT05274269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ELX/TEZ/IVA
Description: Fixed-dose combination (FDC) tablets for oral administration.
Study NCT05274269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVA
Description: Tablet for oral administration.
Study NCT05274269 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (matched to ELX/TEZ/IVA)
Description: Placebo matched to ELX/TEZ/IVA for oral administration.
Study NCT06605131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GP+Toripalimab+CCRT
Description: 1. Induction Chemotherapy (GP Regimen combined with Toripalimab):~1. GP Regimen Gemcitabine: 1000 mg/m² on Day 1 and Day 8; Cisplatin (DDP): 80 mg/m² on Day 1-3; every 3 weeks for 3 cycles.~2. Toripalimab: For patients weighing ≥ 40 kg: 240 mg on Day 1; For patients weighing less than 40 kg: 3 mg/kg; every 3 weeks for 3 cycles.~2. Concurrent Chemoradiotherapy (CCRT): Cisplatin (DDP): 100 mg/m², starting on the first day of radiotherapy; every 3 weeks for 3 cycles
Study NCT06605131 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GP+CCRT
Description: 1. Induction Chemotherapy (GP Regimen ): Gemcitabine: 1000 mg/m² on Day 1 and Day 8; Cisplatin (DDP): 80 mg/m² on Day 1-3; every 3 weeks for 3 cycles.~2. Concurrent Chemoradiotherapy (CCRT): Cisplatin (DDP): 100 mg/m², starting on the first day of radiotherapy; every 3 weeks for 3 cycles
Study NCT04677816 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Neoadjuvant Chemotherapy (NAC)
Description: Participants will receive standard of care neoadjuvant chemotherapy with doxorubicin (60 mg/m2) and cyclophosphamide (600 mg/m2) for 4 cycles and paclitaxel (80 mg/m2) weekly for 12 cycles. Doxorubicin and cyclophosphamide (AC) may be administered on a classical every 3 week or dose dense every 2-week (with growth factor support) schedule at the treating physician's discretion. Routine incorporation of carboplatin is not required, however use of carboplatin (AUC 1.5 to 2 weekly or AUC 6 on week 1, 4, 7, and 10) with paclitaxel is allowed at the treating investigator's discretion.~Upon completion of neoadjuvant chemotherapy, all patients will undergo definitive surgery with either breast conservation or mastectomy with axillary lymph node staging. Type of surgery will be determined by the treating physician.
Study NCT04677816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care Neoadjuvant Chemotherapy (NAC)
Description: Participants will receive standard of care neoadjuvant chemotherapy with doxorubicin (60 mg/m2) and cyclophosphamide (600 mg/m2) for 4 cycles and paclitaxel (80 mg/m2) weekly for 12 cycles. Doxorubicin and cyclophosphamide (AC) may be administered on a classical every 3 week or dose dense every 2-week (with growth factor support) schedule at the treating physician's discretion. Routine incorporation of carboplatin is not required, however use of carboplatin (AUC 1.5 to 2 weekly or AUC 6 on week 1, 4, 7, and 10) with paclitaxel is allowed at the treating investigator's discretion.~Upon completion of neoadjuvant chemotherapy, all patients will undergo definitive surgery with either breast conservation or mastectomy with axillary lymph node staging. Type of surgery will be determined by the treating physician.
Study NCT04677816 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Participants with deficient levels of vitamin D will receive vitamin D supplementation at the initiation of chemotherapy with 50,000 IU of oral vitamin D3 (cholecalciferol) once a week to be continued for 20 weeks during neoadjuvant chemotherapy.